Scientists find way to target cells resistant to chemo

April 24, 2014

Scientists from The University of Manchester have identified a way to sensitise cancer cells to chemotherapy - making them more open to treatment.

The study published today in Cell Reports, could pave the way for the development of drugs to target cells that have become resistant to treatment.

The research team made the discovery whilst exploring the possible mechanisms behind resistance to drugs like Paclitaxel, often used to treat breast and colon cancer.

Dr Andrew Gilmore, who led the research team at The University of Manchester, is part of both the Wellcome Trust Centre for Cell-Matrix Research and also the Manchester Cancer Research Centre.

He said: "Cells replicate and divide through a process known as mitosis. This process is carefully controlled and if any mistake is made during normal division then the cell undergoes apoptosis – otherwise known as controlled cell death.

"Failure of cells to complete mitosis correctly can be the start of cancer. We wanted to understand how this failure – delay of - activates apoptosis, and why some may be able to avoid being killed."

Cancer cells replicate rapidly, and such as paclitaxel target mitosis as a way to kill these quickly dividing cells. But cancer cells can develop resistance to the drugs.

The researchers found a particular protein known as 'Bid' in , and looked at what happened when Bid was switched on.

Their results show that Bid is turned on as cells prepare to divide. This primes the cells to die if cell division takes too long. Cancer cells that were resistant to chemotherapy still turned Bid on, but went through mitosis too quickly for it to kill the cell. However, these resistant cells could be made to die by directly targeting the part of the cell where Bid works.

"Our findings demonstrate that Bid plays a central role in mitosis-related cell death. This opens up new areas of research into drugs that might be able to kill cancer cells that have become resistant to chemotherapy. This could eventually be of huge benefit in a clinical setting and help patients who suffer from advanced stages of ," added Dr Gilmore.

Explore further: Combining cell replication blocker with common cancer drug kills resistant tumor cells

Related Stories

Combining cell replication blocker with common cancer drug kills resistant tumor cells

April 4, 2014
(Medical Xpress)—Researchers from the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter, have found that an agent that inhibits mitochondrial division can overcome tumor cell resistance ...

Cancer stem cells linked to drug resistance

April 20, 2014
Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered a molecule, ...

Cells do not repair damage to DNA during mitosis because telomeres could fuse together

March 20, 2014
Throughout a cell's life, corrective mechanisms act to repair DNA strand breaks. The exception is during the critical moment of cell division, when chromosomes are most vulnerable. Toronto researchers found out why DNA repair ...

Zombie cancer cells eat themselves to live

April 5, 2014
A University of Colorado Cancer Center study recently published in the journal Cell Reports and presented today at the American Association for Cancer Research (AACR) Annual Conference 2014 shows that the cellular process ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.